Drug-induced Pulmonary Hypertension Symposium:
Applying Lessons Learned from The Aminorex Epidemic
2nd Meeting of the International Collaborative
April 13-14, 2023 • Hoover Institution - David & Joan Traitel Building, Stanford, CA
HYBRID (In-person or Virtual)
Pulmonary hypertension (PH) is a rare and fatal cardiopulmonary disease which disproportionately impacts women. Despite the progress in the diagnosis, clinical care, and treatment of PH patients, unique etiological factors are still being discovered. Iatrogenic forms of PH are one of the leading but under-appreciated causes of the disease in the modern era.
The rationale for this symposium is to leverage subject-matter expertise from international academic centers and Stanford University, engage the broader academic communities, global organizations (World Health Organization, United States Food and Drug Administration, European Medicines Agency), and stake-holders (patients, industry partners, etc) to develop a deeper understanding of “drug induced pulmonary hypertension” and establish pharmacovigilance protocols for monitoring drug safety and rapid identification of PH in at-risk populations.
Symposium Steering Committee
Roham Zamanian, MD, FACCP
Associate Professor, Pulmonary
Allergy & Critical Care Medicine, Stanford University
Director, Adult PH Program
Irene Lang, MD
Professor, Vascular Biology, at the Medical University of Vienna
Gérald Simonneau, MD, PhD
Université Paris-Saclay, France
Marc Humbert, MD, PhD
Professor of Respiratory Medicine at the Université Paris-Saclay in Le Kremlin-Bicêtre, France
Meinhard Kneussl, MD
Professor of Respiratory Medicine
Medical University of Vienna,
Chair of Cardio-Respiratory Medicine
Sigmund Freud University of Vienna
The Drug Induced Pulmonary Hypertension Symposium is supported by generous CME grants from J&J, Merck, United Therapeutics, and Gossamerbio, as well as the following sponsors.